We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+1.73%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$124M
AUM Growth
-$34.4M
Cap. Flow
-$23.6M
Cap. Flow %
-19.02%
Top 10 Hldgs %
58.94%
Holding
58
New
20
Increased
14
Reduced
17
Closed
6

Top Buys

Rank Stock Value
1
INO icon
Inovio Pharmaceuticals
INO
+$4.65M
2
TELA icon
TELA Bio
TELA
+$3.5M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$3.18M
4
IKT icon
Inhibikase Therapeutics
IKT
+$2.82M
5
OPTN
OptiNose
OPTN
+$1.84M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$11.8M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$7.77M
3
RPRX icon
Royalty Pharma
RPRX
+$6M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$5.3M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIR icon
26
Vir Biotechnology
VIR
$1.5B
$1.2M 0.97%
+164,106
New +$1.29M
MIST icon
27
Milestone Pharmaceuticals
MIST
$143M
$1.18M 0.95%
500,000
-499,790
-50% -$858K
ANIP icon
28
ANI Pharmaceuticals
ANIP
$1.83B
$1.13M 0.91%
+20,400
New +$1.17M
HRTX icon
29
Heron Therapeutics
HRTX
$94.1M
$1.07M 0.86%
+700,000
New +$1.13M
XGN icon
30
Exagen
XGN
$113M
$1.03M 0.83%
251,049
-283,349
-53% -$1.02M
TSVT
31
DELISTED
2seventy bio
TSVT
$882K 0.71%
300,000
+200,000
+200% +$820K
ITOS
32
DELISTED
iTeos Therapeutics
ITOS
$845K 0.68%
110,000
+80,000
+267% +$687K
PMVP icon
33
PMV Pharmaceuticals
PMVP
$60.3M
$809K 0.65%
+535,805
New +$849K
KZR
34
DELISTED
Kezar Life Sciences
KZR
$739K 0.6%
110,000
-39,131
-26% -$292K
AYTU icon
35
AYTU BioPharma
AYTU
$23.1M
$693K 0.56%
407,549
-93,409
-19% -$171K
ACET icon
36
Adicet Bio
ACET
$84.7M
$673K 0.54%
43,750
+5,660
+15% +$107K
KPRX icon
37
Kiora Pharmaceuticals
KPRX
$11.3M
$663K 0.54%
200,970
-1,430
-0.7% -$4.94K
XERS icon
38
Xeris Biopharma Holdings
XERS
$1.45B
$618K 0.5%
+182,317
New +$586K
AQST icon
39
Aquestive Therapeutics
AQST
$467M
$570K 0.46%
+160,000
New +$738K
APRE icon
40
Aprea Therapeutics
APRE
$7.86M
$491K 0.4%
149,221
+12,047
+9% +$40.3K
SLRN
41
DELISTED
ACELYRIN
SLRN
$417K 0.34%
+132,870
New +$643K
CHRS icon
42
Coherus Oncology
CHRS
$227M
$345K 0.28%
+250,000
New +$280K
PYPD icon
43
PolyPid
PYPD
$83.8M
$315K 0.25%
103,668
-34,836
-25% -$115K
HLVX
44
DELISTED
HilleVax
HLVX
$274K 0.22%
+132,347
New +$249K
ANTX icon
45
AN2 Therapeutics
ANTX
$192M
$271K 0.22%
+196,732
New +$239K
VNDA icon
46
Vanda Pharmaceuticals
VNDA
$312M
$120K 0.1%
+25,000
New +$120K
ELEV
47
DELISTED
Elevation Oncology
ELEV
$113K 0.09%
+200,000
New +$118K
ABVX
48
Abivax
ABVX
$10.8B
$110K 0.09%
+15,000
New +$138K
ALLR
49
Allarity Therapeutics
ALLR
$19.6M
$78.7K 0.06%
+67,289
New +$89.2K
RVNC
50
DELISTED
Revance Therapeutics, Inc.
RVNC
$70.7K 0.06%
23,264
-796,736
-97% -$3.47M
1
2
3

Similar funds

ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Stonepine Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Stonepine Capital Management held 58 positions worth $124M, down 22% from $158M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Stonepine Capital Management withdrew a net $23.6M in Q4 2024, closing 6 positions and reducing 17 holdings. Its most notable exit was Royalty Pharma, an estimated $6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Inovio Pharmaceuticals worth $1.92M.

  • Stonepine Capital Management's largest Q4 2024 buy was Inovio Pharmaceuticals: 1,050,000 shares worth $1.92M.
  • Stonepine Capital Management added most to TELA Bio in Q4 2024, an estimated $3.5M increase.
  • Stonepine Capital Management's biggest Q4 2024 reduction was ADMA Biologics, cutting an estimated $11.8M.
  • Stonepine Capital Management fully exited Royalty Pharma in Q4 2024, selling an estimated $6M.
  • Stonepine Capital Management's ten largest holdings make up 59% of its $124M portfolio in Q4 2024.
  • Stonepine Capital Management opened 20 new positions and closed 6 in Q4 2024.
  • Stonepine Capital Management's portfolio value fell 22% quarter-over-quarter to $124M.

Based on Stonepine Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.